Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q2 FY26 Earnings Presentation
18 slides from Dr. Reddy's Laboratories's earnings presentation, Oct 24, 2025
Slide 1: Regulation 30 intimation cover letter – Q2 FY26 results presentation
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com October 24, 2025 National Stock Exchange of India Ltd. (Scrip Co
Slide 2: Q2FY26 Results Update
\ Dr. Reddy’s Q2FY26 RESULTS UPDATE 24 OCTOBER 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 4: Financial Highlights
Q2FY26 Financial Highlights Near double-digit growth and steady profitability Dr.Reddy’s es Revenues = 8,805 cr PB as%yvoy H 3%aQ0a UNDERLYING FINANCIALS (adjusted for One-off) EBITDA | EBITDA % 22,351 crj26.7% ° Reames _—_Uncertying % 27.5% 21.6% Bsxyvoy BH 3%Q0Q + Reported EBITDA Margin @26.7% PBT
Slide 5: Business Highlights
Q2FY26 Business Highlights Continued progress on strategic priorities Dr.Reddy’s + Acquired Stugeron® & related brands for 18 markets in APAC (incl. key markets India & Vietnam) as well as EMEA * Launched 2 novel, Gastro-Intestinal drugs in India — Tegoprazan as ‘PCAB® & Linaclotide as ‘Colozo™ + Pa
Slide 6: Other Highlights
Q2FY26 Other Highlights Dr.Reddy’s ESG OTHER UPDATES + MSCI ESG Rating of ‘A’ for 2" consecutive year + FTO-11, CTO-5 Middleburgh classified as ‘VAI’, post GMP inspections + Morningstar Sustainalytics' ESG Risk Rating improved to 18.4 (low risk) + USFDA conducted PAI at biologics facility (Bachupall
Slide 7: Revenue Split
Q2FY26 Revenue Split Dr.Reddy’s Qi Broad-based growth, moderated by softness in US generics REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe* GLOBAL GENERICS z 3,241 Cr z 1,376 Cr 89% Bisx%yor BS 5%a0a PSAI 11% OTHERS 0% Global Generics PSAI =7,850 cr 7945 cr Br0%YoY 4%Q00 B12%YoY @ 16%
Slide 8: Key Financial Metrics
Key Financial Metrics Sustaining growth & profitability, while investing for the future REVENUES (&Cr) Q2FY26 EE 8,805 QIFY26 Q4FY25 Q3FY25 Q2FY25 EPS @) 8, 8,016 8,545 8,506 359 Q2FY26 i 17.3 QIFY26 Q4FY25 Q3FY25 *Q2FY25 “Adjusted for 1:5 stock spit 17.0 19.1 16.9 15.0 GROSS MARGINS (% of Revenues)
Slide 9: North America Performance
Q2FY26 North America Performance Dr.Reddy’s @ Impacted due to price erosion, lower Lenalidomide sales MARKET PERFORMANCE >) -2.1% vs -0.1% DRL Growth vs US Generic Market (Excl. Lenalidomide) “As per |QVIA MAT Aug’ 25 NEW LAUNCHES Revenues 7 12 23,241 Cr Q2FY26 —- HIFY26 NEW ANDA FILINGS 5 6 Decline
Slide 10: India Performance
Q2FY26 India Performance Double-digit growth delivery ~ MARKET PERFORMANCE* 18% 9.4% vs 7.8% DRL MAT Growth vs IPM IPM RANK #9 =#10 Revenues FTM = MQT & MAT Sep'25 Sep'25 21,578 cr we THERAPY LEADERHIP* #1 #2 Growth Drivers : New brand launches, STOMATOLOGICALS VACCINES improved pricing & higher vol
Slide 11: Emerging Markets Performance
Q2FY26 Emerging Markets Performance New product launches & favourable forex driving growth Dr.Reddy’s @ » KEY UPDATES ws COUNTRIES PRESENT IN 48 + Launched Skorolox, first INN loxoprofen in Russia, indicated for treatment of acute upper respiratory tract infections NEW PRODUCT LAUNCHES Revenues z 1,
Slide 12: Europe Performance
Q2FY26 Europe Performance Dr.Reddy’s @ Growth underpinned by acquired NRT business pé KEY UPDATES COUNTRIES PRESENT IN + NRT integration progressing well : 2/3rd business value integrated a 20 - Canada, Australia & some Western European countries now completed Revenues NEW PRODUCT 21,376 cr LAUNCHES
Slide 13: PSAI Performance
Q2FY26 PSAI Performance Dr.Reddy’s Qs Lower operating leverage and product mix shifts weigh on margins » 10% | GROSS MARGIN 18% vs 30% Q2FY26 vs Q2FY25 Revenues 7945 cr B12%YoY B 16%Q0Q DMF FILINGS 37. 49 Growth Drivers : New product launches, H Q2FY26 = HIFY26 favourable forex Historical Revenues (
Slide 14: In Summary
In Summary A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS © ADVANCE KEY PIPELINE PRODUCTS (SEMAGLUTIDE, ABATACEPT) DRIVE EFFICIENCIES THROUGH BETTER OPERATIONAL LEVERAGE 39 }=AUGMENT ORGANIC GROWTH WITH M&A and IN-LICENSING STRENGTHEN CAPABILITIES — PE
Slide 15: Consolidated Income Statement
Consolidated Income Statement DrReddy’s @ Particulars (& Cr) Q2FY26 Q2FY25 YoY Gr% QiFY26 QoQ Gr% HIFY26 HIFY25 YoY Gr % Revenues 8,805 8,016 10 8,545 3 47,350 15,689 "1 Cost of Revenues 3,991 3,239 23 3,682 8 7673 6,278 22 Gross Profit 4,814 4777 1 4,863 (1) 9,677 9,411 3 % of Revenues 54.7% 59.6%
Slide 16: At a glance
At a glance Dr.Reddy’s @: We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. ~756mn patients reached globally $3.8bn Revenue 17% Revenue Growth 28% EBITDA Margin ~28% Roce 26,000+ Employees globally 57 Nationalities (Employees) 83 Markets served 32 Plants (Ma
Slide 17: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 18: Good Health Can't Wait.
a es 6) } } Good Health Can’t Wait.
DR Reddys Laboratories — Q2 FY26 Earnings Presentation on 6ix